Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

Add To Watchlist

GREY:ATBPF - Post Discussion

Antibe Therapeutics Inc(Pre-Merger) > Scenario

View:

Post by MasterAlgae on Nov 26, 2020 4:50pm

Scenario

I'd think that about 625 million would be a realistic cash buyout of ATB-346 - likely without a large licensing agreement.

Antibe's other early-stage clinical development assets could then be rapidly advanced with different studies ongoing at the same time.

Then, based on the likelyhood of positive efficacy and test result advancements the company would become a billion dollar acquisiton target by the mega-cap pharma which purchased ATB-346.

And they all lived happily ever after!

869

Comment

Comment by MrMugsy on Nov 26, 2020 5:00pm

I have agreed with you on that number for a long time MasterAlgae ... but ... I also think there's a lot more the company needs to share with us before we know for sure. For example, now that we can do a DCF based on the business case data, I scratch my head at a mear $600+ M. It seems too low. If the company plans to go after additional indications in short order ... the DCF valuation ...more

209

Comment

Antibe Therapeutics Inc(Pre-Merger)